

Biocan Novel DHPPi L4

Authorised

- Canine distemper virus, strain CDV Bio 11/A, Live
- Canine adenovirus 2, strain CAV-2-Bio 13, Live
- Canine parvovirus 2b, strain CPV-2b Bio 12/B, Live
- Canine parainfluenza virus, strain CPIV-2-Bio 15, Live
- Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain MSLB 1089, Inactivated
- Leptospira interrogans, serogroup Canicola, serovar Canicola, strain MSLB 1090, Inactivated
- Leptospira interrogans, serogroup Australis, serovar Bratislava, strain MSLB 1088, Inactivated
- Leptospira kirschneri, serogroup Grippotyphosa, serovar Grippotyphosa, strain MSLB 1091, Inactivated

Product identification

Medicine name:

Biocan Novel DHPPi L4

Biocan Novel DHPPi/L4, liofilizatas ir skiediklis injekcinei suspensijai ruošti šunims

Active substance:

Canine distemper virus, strain CDV Bio 11/A, Live

Canine adenovirus 2, strain CAV-2-Bio 13, Live

Canine parvovirus 2b, strain CPV-2b Bio 12/B, Live

Canine parainfluenza virus, strain CPIV-2-Bio 15, Live

Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain MSLB 1089, Inactivated

Leptospira interrogans, serogroup Canicola, serovar Canicola, strain MSLB 1090, Inactivated

Leptospira interrogans, serogroup Australis, serovar Bratislava, strain MSLB 1088, Inactivated

Leptospira kirschneri, serogroup Grippotyphosa, serovar Grippotyphosa, strain MSLB 1091, Inactivated

Target species:

Dog

Route of administration:

Subcutaneous use

Product details

Active substance and strength:

Canine distemper virus, strain CDV Bio 11/A, Live

5.10 log₁₀ tissue culture infective dose 50 / 1.00 Dose

Canine adenovirus 2, strain CAV-2-Bio 13, Live

5.30 log₁₀ tissue culture infective dose 50 / 1.00 Dose

Canine parvovirus 2b, strain CPV-2b Bio 12/B, Live

6.60 log₁₀ tissue culture infective dose 50 / 1.00 Dose

Canine parainfluenza virus, strain CPiV-2-Bio 15, Live

5.10 log₁₀ tissue culture infective dose 50 / 1.00 Dose

Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar

Icterohaemorrhagiae, strain MSLB 1089, Inactivated

51.00 Antibody microagglutination-lytic reaction / 1.00 Dose

Leptospira interrogans, serogroup Canicola, serovar Canicola, strain MSLB 1090,

Inactivated

51.00 Antibody microagglutination-lytic reaction / 1.00 Dose

Leptospira interrogans, serogroup Australis, serovar Bratislava, strain MSLB 1088,

Inactivated

51.00 Antibody microagglutination-lytic reaction / 1.00 Dose

Leptospira kirschneri, serogroup Grippotyphosa, serovar Grippotyphosa, strain MSLB

1091, Inactivated

40.00 Antibody microagglutination-lytic reaction / 1.00 Dose

Pharmaceutical form:

Lyophilisate and solvent for suspension for injection

Withdrawal period by route of administration:

Subcutaneous use:

-

Dog

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI07AI02

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Lithuania

Package description:

Glass Vial

Glass Vial

Glass Vial

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Bioveta a.s.

Marketing authorisation date:

2/11/2014

Manufacturing sites for batch release:

Bioveta a.s.

Responsible authority:

State Food And Veterinary Service

Authorisation number:

LT/2/14/2250/001-003

Date of authorisation status change:

26/01/2020

Reference member state:

Czechia

Procedure number:

CZ/V/0125/001

Concerned member states:

Bulgaria Croatia Cyprus Estonia Hungary Latvia Lithuania Malta Poland
Romania Slovakia Slovenia

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

RV2250.pdf

Source URL: <https://medicines.health.europa.eu/veterinary/600000053291>